Novavax COVID-19 vaccine trial results suggest it is highly effective in preventing symptomatic infections and hospitalizations

Novavax’s Phase 3 COVID-19 vaccine trial results suggest the vaccine may be applicable for distribution. Results show the two-shot vaccine is effective in preventing symptomatic infections, severe illness, and hospitalizations.

The study was conducted on 30,000 adults. 77 participants contracted COVID-19, only 14 of which were in the group that received the vaccine (the others were given a fake vaccine). None of the vaccine group participants experienced severe side effects. According to Novavax, the vaccine trial suggests a 90% effectiveness against lab-proven symptomatic infection and 93% against virus variants.

These rates are in the same range as vaccines produced by Pfizer-BioNTech and Moderna. However, these vaccines are still under review for full Food and Drug Administration approval. Currently, the FDA has only approved COVID-19 vaccines for emergency use. Since the US has been successful in producing and distributing vaccines, the Novavax vaccine seeks to aid the international community. “Many of our first doses will go to … low- and middle-income countries, and that was the goal to begin with,” Novavax CEO Stanley Erck said.


The following two tabs change content below.
Antoinette is a community college student in Sacramento, California. She is a Politics Editor at Fact Based America, a correspondent for Campus Reform, and a student journalist. She previously worked for Turning Point USA as a High School Coordinator.

Leave a Reply